Emerging targeted therapies for melanoma

Expert Opinion on Emerging Drugs

Volumn 21, Issue 2, 2016, Pages 195-207

  Johnson, Douglas B ^a   Pollack, Megan H ^b   Sosman, Jeffrey A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

binimetinib; BRAF; cobimetinib; glembatumumab vedotin; imatinib; KIT; Melanoma; NRAS; targeted therapy; trametinib

Indexed keywords

ANTIBODY CONJUGATE; B RAF KINASE; BINIMETINIB; COBIMETINIB; CYCLIN DEPENDENT KINASE INHIBITOR; GLEMBATUMUMAB VEDOTIN; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SELUMETINIB; TALIMOGENE LAHERPAREPVEC; TRAMETINIB; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL CYCLE; DRUG MEGADOSE; HUMAN; MELANOMA; REVIEW; TARGET CELL; DRUG DESIGN; GENETICS; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84975221154     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1080/14728214.2016.1184644     Document Type: Review

References (75)

1. E.L.Korn, P.Y.Liu, S.J.Lee, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527–534.
2. R.L.Siegel, K.D.Miller, A.Jemal Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
3. H.Davies, G.R.Bignell, C.Cox, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954.
4. E.Hodis, I.R.Watson, G.V.Kryukov, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251–263.• Comprehensive analysis of genetic alterations in melanoma.
5. M.F.Berger, E.Hodis, T.P.Heffernan, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485:502–506.
6. M.Krauthammer, Y.Kong, B.H.Ha, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44:1006–1014.
7. M.B.Atkins, M.T.Lotze, J.P.Dutcher, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116.
8. J.M.Kirkwood, J.Manola, J.Ibrahim, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670–1677.
9. P.C.Tumeh, C.L.Harview, J.H.Yearley, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–571.
10. S.A.Rosenberg, J.C.Yang, S.L.Topalian, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907–913.
11. F.S.Hodi, S.J.O’Day, D.F.McDermott, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
12. P.A.Prieto, J.C.Yang, R.M.Sherry, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039–2047.
13. D.Schadendorf, F.S.Hodi, C.Robert, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894.
14. C.Robert, J.Schachter, G.V.Long, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
15. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
16. C.Robert, G.V.Long, B.Brady, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
17. P.B.Chapman, A.Hauschild, C.Robert, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516.
18. A.Hauschild, J.J.Grob, L.V.Demidov, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–365.
19. K.T.Flaherty, C.Robert, P.Hersey, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–114.
20. K.T.Flaherty, J.R.Infante, A.Daud, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703.
21. C.Robert, B.Karaszewska, J.Schachter, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.• Phase III randomized study demonstrating improved clinical outcomes with combined BRAF and MEK inhibitors. Also see references 22 and 23.
22. G.V.Long, D.Stroyakovskiy, H.Gogas, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–451.
23. J.Larkin, P.A.Ascierto, B.Dreno, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–1876.
24. J.A.Curtin, K.Busam, D.Pinkel, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–4346.
25. F.S.Hodi, C.L.Corless, A.Giobbie-Hurder, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31:3182–3190.• Phase II study demonstrating activity of imatinib in KIT mutant melanoma and suggesting which mutations respond to treatment.
26. M.R.Middleton, J.J.Grob, N.Aaronson, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–166.
27. B.L.Liu, M.Robinson, Z.Q.Han, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292–303.
28. R.H.Andtbacka, H.L.Kaufman, F.Collichio, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788.
29. K.E.Hutchinson, D.Lipson, P.J.Stephens, et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res. 2013;19:6696–6702.
30. P.A.Ott, O.Hamid, A.C.Pavlick, et al. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol. 2014;32:3659–3666.• Phase II study showing activity of glembatumumab vedotin in advanced melanoma.
31. D.B.Johnson, A.M.Menzies, L.Zimmer, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015;51:2792–2799.
32. G.S.Falchook, K.D.Lewis, J.R.Infante, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:782–789.
33. K.B.Kim, R.Kefford, A.C.Pavlick, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31:482–489.
34. K.B.Dahlman, J.Xia, K.Hutchinson, et al. BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012;2(9):791–797.• Pre-clinical and clinical evidence for MEK inhibitors in atypical (non-V600) BRAF mutant melanoma.
35. A.M.Menzies, I.Yeh, T.Botton, et al. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell Melanoma Res. 2015;28(5):607–610.
36. C.D.van Raamsdonk, V.Bezrookove, G.Green, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599–602.
37. C.D.Van Raamsdonk, K.G.Griewank, M.B.Crosby, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191–2199.
38. R.J.Sullivan, J.S.Weber, S.P.Patel, et al. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment [Abstract]. J Clin Oncol. 2015;33:9007.
39. P.A.Ascierto, D.Schadendorf, C.Berking, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14:249–256.•• First study demonstrating significant activity of targeted therapy in NRAS mutant melanoma.
40. Array BioPharma Announces Phase 3 Binimetinib Trial Meets Primary Endpoint For NRAS-Mutant Melanoma. [cited 2016 Jan19]. Available from: http://www.prnewswire.com/news-releases/array-biopharma-announces-phase-3-binimetinib-trial-meets-primary-endpoint-for-nras-mutant-melanoma-300193548.html
41. J.Larkin, Y.Yan, G.A.McArthur, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma [Abstract]. J Clin Oncol. 2015;33:9006.
42. US FDA. Cotellic (cobimetinib) tablets: prescribing information. 2015 [cited 2016 Jan6]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf
43. Y.Isshiki, Y.Kohchi, H.Iikura, et al. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg Med Chem Lett. 2011;21:1795–1801.
44. https://www.astrazeneca.com/our-company/media-centre/press-releases/2015/astrazeneca-selumetinib-uveal-melanoma-oncology-22072015.html
45. J.M.Kirkwood, L.Bastholt, C.Robert, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012;18:555–567.
46. R.D.Carvajal, J.A.Sosman, J.F.Quevedo, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311:2397–2405.• First study reporting improved outcomes for any agent in uveal melanoma.
47. L.Zimmer, F.Barlesi, M.Martinez-Garcia, et al. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin Cancer Res. 2014;20(16):4251–4261.
48. R.J.Young, K.Waldeck, C.Martin, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 2014;27(4):590–600.
49. U.Asghar, A.K.Witkiewicz, N.C.Turner, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–146.
50. N.C.Turner, J.Ro, F.Andre, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219.
51. J.A.Sosman, M.Kittaneh, M.P.J.Lolkema, et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. J Clin Oncol. 2014;32:9009.
52. L.N.Kwong, J.C.Costello, H.Liu, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18:1503–1510.
53. G.Chen, N.Chakravarti, K.Aardalen, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014;20:5537–5546.
54. W.Peng, J.Q.Chen, C.Liu, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6(2):202–216.
55. E.Jokinen, J.P.Koivunen. MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Ther Adv Med Oncol. 2015;7:170–180.
56. R.Nazarian, H.Shi, Q.Wang, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–977.
57. F.Su, A.Viros, C.Milagre, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207–215.
58. C.Zhang, W.Spevak, Y.Zhang, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526:583–586.• Pre-clinical evidence of a RAF inhibitor that avoids paradoxical MAPK activation.
59. E.J.Morris, S.Jha, C.R.Restaino, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013;3:742–750.
60. D.J.Wong, L.Robert, M.S.Atefi, et al. Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014;13:194.• Pre-clinical report of effective ERK inhibition.
61. K.L.Jameson, P.K.Mazur, A.M.Zehnder, et al. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med. 2013;19:626–630.
62. L.Naumovski, J.R.Junutula. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010;12:248–257.
63. A.A.Rose, A.A.Grosset, Z.Dong, et al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res. 2010;16:2147–2156.
64. D.A.Yardley, R.Weaver, M.E.Melisko, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol. 2015;33:1609–1619.
65. J.Bendell, M.Saleh, A.A.Rose, et al. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2014;32:3619–3625.
66. R.D.Carvajal, C.R.Antonescu, J.D.Wolchok, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327–2334.
67. J.Guo, L.Si, Y.Kong, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904–2909.
68. J.H.Cho, K.M.Kim, M.Kwon, et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs. 2012;30:2008–2014.
69. P.M.LoRusso, S.A.Boerner, M.J.Pilat, et al. Pilot trial of selecting molecularly guided therapy for patients with non-V600 BRAF-mutant metastatic melanoma: experience of the SU2C/MRA melanoma dream team. Mol Cancer Ther. 2015;14:1962–1971.
70. K.B.Kim, J.A.Sosman, J.P.Fruehauf, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012;30:34–41.
71. J.Fruehauf, J.Lutzky, D.McDermott, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011;17:7462–7469.
72. P.G.Corrie, A.Marshall, J.A.Dunn, et al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 2014;15:620–630.
73. F.S.Hodi, D.Lawrence, C.Lezcano, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632–642.• Demonstration of activity of angiogenesis inhibition in combination with immunotherapy.
74. C.Xia, R.Leon-Ferre, D.Laux, et al. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother Pharmacol. 2014;74:691–697.
75. R.S.Herbst, J.C.Soria, M.Kowanetz, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–567.